Table 1

Clinical and baseline characteristics of study patients

Patients without events (−)
(N=145)
Patients with events (+)
(N=43)
p Value
Age, years*66.0 (56.0–72.0)69.0 (65.0–74.0)0.009
Male, n (%)94 (64.8)20 (46.5)0.034
Height, cm161.2±9.43157.3±10.20.023
Weight, kg63.5±11.261.2±12.80.253
Systolic BP, mm Hg126.2±13.8121.1±23.50.080
Diastolic BP, mm Hg74.9±11.977.8±11.20.170
Heart rate, bpm71.3±11.568.0±9.810.083
Haemoglobin, g/dL13.2±1.913.1±1.90.683
Blood urea nitrogen, mg/dL*17.0 (13.0–21.0)18.0 (14.0–23.5)0.203
Creatinine, mg/dL*1.0 (0.8–1.2)1.0 (0.9–1.2)0.953
Sodium, mEq/L*143 (140–144)142 (139–144)0.314
Potassium, mEq/L4.3±0.54.4±0.40.882
Medical history
 Ischaemic heart disease, n (%)21 (14.5)10 (23.3)0.240
 Heart failure, n (%)2 (1.4)3 (7.0)0.080
 Diabetes mellitus, n (%)21 (14.5)8 (18.6)0.482
 Hypertension, n (%)73 (50.3)23 (53.5)0.732
 Stroke, n (%)20 (13.8)6 (14.0)1.000
Medication
 β-blockers, n (%)69 (47.9)28 (65.1)0.056
 Calcium channel blockers, n (%)40 (27.8)15 (34.9)0.446
 ACEI/ARBS, n (%)59 (40.7)19 (44.2)0.726
 Antiplatelet, n (%)65 (44.8)22 (51.2)0.490
 Anticoagulation, n (%)12 (8.3)2 (4.7)0.528
  • Events comprising the occurrence of new onset of atrial fibrillation, stroke, heart failure, and cardiovascular death.

  • *Median (IQR), comparison was made using Mann-Whitney test.

  • ACEI/ARBS, ACE inhibitor/angiotensin receptor blockers; BP, blood pressure.